Apreo Health announced its emergence from stealth and an upcoming presentation of first-in-human clinical data for its emphysema treatment.
Menlo Park, California-based Apreo develops the Breathe airway scaffold. It designed the first-of-its-kind implant to relieve pressure in overinflated lungs without removing or sacrificing healthy tissue.
Related: RebrAIn secures MDR Certification for its OptimMRI Platform
The company says traditional interventions have limitations and carry significant complication rates. Its approach aims to reach more patients and integrate more seamlessly into clinical practice.
BREATHE 1&2, the company’s feasibility studies, enrolled 60 patients across five sites in Australia and Europe. The studies evaluated the Breathe device in patients with severe emphysema and lung hyperinflation. Apreo plans to unveil findings at the American Thoracic Society (ATS) 2025 International Conference next week in San Francisco.
The company says its data highlights its progress toward a broadly applicable treatment option. It targets patients previously underserved by pharmacological and interventional therapies. It has preparations underway for its next phase of clinical development, according to a news release.
“Severe emphysema has remained one of the most vast unmet needs in respiratory care,” said Karun Naga, CEO of Apreo Health. “Apreo’s goal from the start was to break through with a solution that offers physicians a non-destructive therapy designed for broad adoption across the majority of emphysema patients with hyperinflation. We’re thrilled to emerge from stealth and share these early data with the clinical community.”
